GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000611925 | Oral cavity | EOLP | oxidative phosphorylation | 33/2218 | 141/18723 | 8.63e-05 | 1.02e-03 | 33 |
GO:19030382 | Oral cavity | EOLP | negative regulation of leukocyte cell-cell adhesion | 33/2218 | 141/18723 | 8.63e-05 | 1.02e-03 | 33 |
GO:003220021 | Oral cavity | EOLP | telomere organization | 36/2218 | 159/18723 | 8.79e-05 | 1.04e-03 | 36 |
GO:00329445 | Oral cavity | EOLP | regulation of mononuclear cell proliferation | 47/2218 | 227/18723 | 8.81e-05 | 1.04e-03 | 47 |
GO:007134621 | Oral cavity | EOLP | cellular response to interferon-gamma | 29/2218 | 118/18723 | 9.03e-05 | 1.05e-03 | 29 |
GO:200006024 | Oral cavity | EOLP | positive regulation of ubiquitin-dependent protein catabolic process | 27/2218 | 107/18723 | 9.64e-05 | 1.12e-03 | 27 |
GO:003052117 | Oral cavity | EOLP | androgen receptor signaling pathway | 15/2218 | 44/18723 | 9.66e-05 | 1.12e-03 | 15 |
GO:190357324 | Oral cavity | EOLP | negative regulation of response to endoplasmic reticulum stress | 15/2218 | 44/18723 | 9.66e-05 | 1.12e-03 | 15 |
GO:004340123 | Oral cavity | EOLP | steroid hormone mediated signaling pathway | 32/2218 | 136/18723 | 9.85e-05 | 1.14e-03 | 32 |
GO:003209223 | Oral cavity | EOLP | positive regulation of protein binding | 23/2218 | 85/18723 | 9.95e-05 | 1.14e-03 | 23 |
GO:004506924 | Oral cavity | EOLP | regulation of viral genome replication | 23/2218 | 85/18723 | 9.95e-05 | 1.14e-03 | 23 |
GO:005134625 | Oral cavity | EOLP | negative regulation of hydrolase activity | 70/2218 | 379/18723 | 9.98e-05 | 1.14e-03 | 70 |
GO:190165513 | Oral cavity | EOLP | cellular response to ketone | 25/2218 | 96/18723 | 9.99e-05 | 1.14e-03 | 25 |
GO:004311223 | Oral cavity | EOLP | receptor metabolic process | 37/2218 | 166/18723 | 1.00e-04 | 1.14e-03 | 37 |
GO:003432917 | Oral cavity | EOLP | cell junction assembly | 76/2218 | 420/18723 | 1.02e-04 | 1.17e-03 | 76 |
GO:007266613 | Oral cavity | EOLP | establishment of protein localization to vacuole | 16/2218 | 49/18723 | 1.03e-04 | 1.17e-03 | 16 |
GO:004259422 | Oral cavity | EOLP | response to starvation | 42/2218 | 197/18723 | 1.03e-04 | 1.17e-03 | 42 |
GO:190289324 | Oral cavity | EOLP | regulation of pri-miRNA transcription by RNA polymerase II | 17/2218 | 54/18723 | 1.05e-04 | 1.19e-03 | 17 |
GO:00508663 | Oral cavity | EOLP | negative regulation of cell activation | 44/2218 | 210/18723 | 1.09e-04 | 1.23e-03 | 44 |
GO:190290424 | Oral cavity | EOLP | negative regulation of supramolecular fiber organization | 37/2218 | 167/18723 | 1.14e-04 | 1.27e-03 | 37 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |